An FRα-targeting monoclonal antibody delivers the maytansinoid payload DM4 to FRα-positive tumor cells. Upon binding and internalization, a cleavable disulfide linker is reduced to release DM4, which inhibits microtubule assembly, leading to mitotic arrest and apoptosis (with potential bystander killing).